Abstract 14642: Intravascular Ultrasound Comparison of Small Coronary Lesions Between the CardioMind Coronary Stent and Conventional Sirolimus-Eluting Stent
Background: The CardioMind Sparrow® stent system consists of a self-expanding, ultra-thin nitinol stent mounted within a 0.014-inch guide wire delivery system having improved flexibility and deliverability. The performance of this novel device with sirolimus in a fully biodegradable polymer (CMI SES) has not been determined. Therefore, the aim was to compare the CMI SES against conventional balloon-expandable sirolimus-eluting stent (SES) in patients with small vessel disease.
Methods: A total of 14 lesions treated with the CMI SES from the CARE II trial, which was a prospective, randomized, multi-center trial in the treatment of single de novo native coronary artery lesions, were compared to 22 small vessel lesions (reference diameter < 2.5 mm) treated with SES from our IVUS core lab data. IVUS examination was performed at post-procedure and 8 months later.
Results: Reference diameter was similar between the 2 groups (CMI SES: 2.23±0.32 vs. SES: 2.25±0.02 mm, p=NS). Stent volume index (VI) of CMI SES was significantly increased during follow-up period and stent VI at follow-up was similar to that of SES. On the other hand, % neointimal volume was significantly greater in CMI SES than that in SES. Therefore, there was a significant difference in lumen VI between CMI SES and SES at follow-up. However, change in lumen VI during follow-up period did not reach statistical significance between CMI SES and SES.
Conclusions: Despite revealing greater amounts of neointimal hyperplasia, this novel stent system with sirolimus presented chronic stent expansion to compensate for neointimal obstruction and thus, preserved the lumen to some extent by increasing stent volumes at follow-up.
- © 2010 by American Heart Association, Inc.